Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema TS ID 10621Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease TS ID 11791Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
AI in retinal scanning MT524 (MIB265)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC